Induction of granzyme B expression in T-cell receptor/CD28-stimulated human regulatory T cells is suppressed by inhibitors of the PI3K-mTOR pathway

被引:0
作者
Olga V Efimova
Todd W Kelley
机构
[1] University of Utah,Department of Pathology
[2] ARUP Laboratories,ARUP Institute for Clinical and Experimental Pathology
来源
BMC Immunology | / 10卷
关键词
FOXP3 Expression; Rapamycin Treatment; PI3K Inhibitor LY294002; Flow Cytometric Evaluation; Hodgkin Lymphoma Cell Line;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 235 条
  • [11] Noelle RJ(2007)IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells J Immunol 178 280-90
  • [12] Cao X(2006)Induction of granzyme B and T cell cytotoxic capacity by IL-2 or IL-15 without antigens: multiclonal responses that are extremely lytic if triggered and short-lived after cytokine withdrawal Cytokine 36 148-59
  • [13] Cai SF(2003)Alcohol consumption decreases IL-2-induced NF-kappaB activity in enriched NK cells from C57BL/6 mice Toxicol Sci 73 72-9
  • [14] Fehniger TA(2006)A novel NF-kappaB binding site controls human granzyme B gene transcription J Immunol 176 4173-81
  • [15] Song J(2007)Altered activation of AKT is required for the suppressive function of human CD4+CD25+ T regulatory cells Blood 109 2014-22
  • [16] Collins LI(2008)The AKT-mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells J Exp Med 205 565-74
  • [17] Piwnica-Worms DR(2004)Distinct IL-2 receptor signaling pattern in CD4+CD25+ regulatory T cells J Immunol 172 5287-96
  • [18] Ley TJ(2007)The influence of immuosuppressive therapy on the development of CD4+CD25+ T cells after renal transplantation Transplant Proc 39 2721-3
  • [19] Gondek DC(2006)Calcineurin inhibitors, but not rapamycin, reduce percentages of CD4+CD25+FOXP3+ regulatory T cells in renal transplant recipients Transplantation 82 550-7
  • [20] Devries V(2008)Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells Blood 111 453-62